VIDEO: High dose ponatinib benefits patients with chronic myeloid leukemia
Click Here to Manage Email Alerts
In this video Richard M. Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana-Farber Institute, spoke with Healio about a study that showed a three-dose schedule of ponatinib with a higher initial dose was superior to other dosing methods for patients with chronic myeloid leukemia.
An analysis of dosing regimens of ponatinib in 283 patients with chronic myeloid leukemia showed that a starting dose of 45 mg daily was most beneficial. Response rates were maintained in most patients even after doses were decreased to 15 mg per day.
"The dose of 45 mg to start, with a ratcheting down to 15 mg per day once major molecular response was achieved, was the best schedule compared with either continuous 15 mg per day dosing or starting at 30 mg and revving down to 15 mg," Stone said. "That was an important confirmatory piece of data," he said.
Collapse
Cortes J, et al. 7502. Presented at: ASCO 2021; June 4-8, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts